This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
3D Printing Firms Join Fight Against Coronavirus-Led Disaster
by Chandrima Sanyal
Here, we discuss the efforts of additive manufacturing companies to improve safety for healthcare workers with 3D-printed materials.
HPQNegative Net Change SSYSPositive Net Change GENegative Net Change DDDPositive Net Change
biotechs computers medical tech-stocks
Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir
by Zacks Equity Research
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change GILDPositive Net Change
biotechs
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
by Zacks Equity Research
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
BIIBPositive Net Change REGNPositive Net Change RHHBYPositive Net Change GILDPositive Net Change MYLPositive Net Change INOPositive Net Change VIRPositive Net Change
biotechs pharmaceuticals
How To Play The W-Shaped Recovery
by Daniel Laboe
Patience is the name of the game during market downturns
TSMNegative Net Change SPLKPositive Net Change SENegative Net Change MSFTNegative Net Change MRNAPositive Net Change MCDNegative Net Change JPMPositive Net Change HDNegative Net Change GILDPositive Net Change DISNegative Net Change BABAPositive Net Change
biotechs cloud-computing coronavirus finance large-cap media semiconductor tech-stocks
Novavax Rallies as Influenza Vaccine Meets All Goals in Study
by Zacks Equity Research
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
SNYPositive Net Change MRNAPositive Net Change NVAXNegative Net Change INOPositive Net Change
biotechs medical pharmaceuticals
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
by Daniel Laboe
It is only a matter of time before this virus anxiety is a thing of the past.
REGNPositive Net Change SNYPositive Net Change GILDPositive Net Change MRNAPositive Net Change INOPositive Net Change
biotechs coronavirus healthcare medical
Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
GILDPositive Net Change NVAXNegative Net Change IMVPositive Net Change HOTHNegative Net Change MISTPositive Net Change
biotechs
CytomX & Astellas Collaborate to Develop Novel Cancer Therapy
by Zacks Equity Research
CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.
BMYPositive Net Change AMGNNegative Net Change ABBVNegative Net Change CTMXNegative Net Change
biotechs
Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.
RVNCPositive Net Change
biotechs
Aytu BioScience to Issue Coronavirus Rapid Test in North America
by Zacks Equity Research
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
MRNAPositive Net Change NVAXNegative Net Change INOPositive Net Change AYTUPositive Net Change
biotechs
Eiger Completes NDA Submission of Progeria Drug Lonafarnib
by Zacks Equity Research
Eiger (EIGR) completes rolling submission of the NDA seeking approval for lonafarnib as a treatment for progeria and progeroid laminopathies, ultra-rare diseases causing accelerated aging in children.
MRKPositive Net Change BMYPositive Net Change EIGRNegative Net Change XERSPositive Net Change
biotechs
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
JNJPositive Net Change REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GILDPositive Net Change LLYNegative Net Change GSKPositive Net Change
biotechs pharmaceuticals
Hoth Surges on Collaboration With Voltron for COVID-19 Vaccine
by Zacks Equity Research
Hoth (HOTH) soars following a joint venture with Voltron Therapeutics for a vaccine for COVID-19.
MRNAPositive Net Change NVAXNegative Net Change INOPositive Net Change HOTHNegative Net Change
biotechs medical pharmaceuticals
Roche Gets FDA Approval for Actemra Trials in COVID-19
by Zacks Equity Research
Roche (RHHBY) gets FDA nod to evaluate Actemra plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
REGNPositive Net Change RHHBYPositive Net Change GILDPositive Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Tech Giants Boost Efforts to Deal With Coronavirus Crisis
by Radhika Pujara
Here we discuss how tech giants including Microsoft (MSFT) and others are leaving no stone unturned to address COVID-19 crisis in innovative ways, backed by AI, ML and cloud computing capabilities.
MSFTNegative Net Change IBMNegative Net Change AMZNNegative Net Change LHPositive Net Change GOOGLNegative Net Change ADPTPositive Net Change
biotechs cloud-computing internet internet-content medical tech-stocks
Coronavirus Scare Supports These Biotech ETFs & Stocks
by Sanghamitra Saha
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
IBBPositive Net Change CNCRNegative Net Change BBHPositive Net Change ARKGPositive Net Change AYTUPositive Net Change FTSVPositive Net Change VIRPositive Net Change IDNAPositive Net Change CODXNegative Net Change
biotechs etfs
Find Strong Stocks During the Coronavirus Crisis with this Filtered Zacks Rank 5 Screener
by Benjamin Rains
Today we are going to utilize our Filtered Zacks Rank 5 Screener to help investors find what could be solid investments when stocks start to recover...
ITGRPositive Net Change EVAPositive Net Change DGICANegative Net Change
biofuels biotechs earnings finance insurance
Axsome Expedites Completion Timeline of AD Study on AXS-05
by Zacks Equity Research
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
MRNAPositive Net Change NVAXNegative Net Change INOPositive Net Change AXSMPositive Net Change
biotechs
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
QGENNegative Net Change DHRPositive Net Change QDELNegative Net Change AYTUPositive Net Change CODXNegative Net Change
biotechs medical
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
by Zacks Equity Research
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
TEVANegative Net Change GILDPositive Net Change MYLPositive Net Change NVSPositive Net Change
biotechs medical pharmaceuticals
Top Ranked Momentum Stocks to Buy for March 23rd
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 23rd.
ZEONNo Net Change REGNPositive Net Change CLXPositive Net Change
biofuels biotechs
Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
GILDPositive Net Change MRNAPositive Net Change NVAXNegative Net Change INOPositive Net Change
biotechs
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
TEVANegative Net Change REGNPositive Net Change SNYPositive Net Change GILDPositive Net Change MYLPositive Net Change BAYRYPositive Net Change
biotechs medical pharmaceuticals
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
MRNAPositive Net Change NVAXNegative Net Change EBSPositive Net Change VXRTPositive Net Change
biotechs
Coronavirus Worries? Screen for Stocks with Management Excellence
by Tracey Ryniec
With the coronavirus sell-off increasing worries about debt, here are 5 companies with low debt to equity ratios.
MSFTNegative Net Change AMATNegative Net Change GRMNNegative Net Change SYNAPositive Net Change INMDPositive Net Change
biotechs value-stocks